Related Experiment Videos
Prolonged cholestasis and ductopenia associated with tenoxicam
Viviane Trak-Smayra1, Dominique Cazals-Hatem, Tarik Asselah
1Department of Pathology, Beaujon Hospital, 100 Boulevard du Général Leclerc, 92118 Clichy Cedex, France.
Journal of Hepatology
|June 25, 2003
Summary
Drug-induced liver injury from Tenoxicam can cause prolonged bile duct destruction (ductopenia). This case highlights potential immunoallergic mechanisms and chronic evolution despite clinical recovery, suggesting compensatory biliary pathways.
Area of Science:
- Hepatology
- Immunology
- Pharmacology
Background:
- Cholestatic liver diseases involve bile duct destruction, with drug-induced causes often having unclear pathophysiology.
- Intra-hepatic bile duct damage and ductopenia can result from various etiologies.
- The natural history of drug-induced cholangiopathies requires further elucidation.
Observation:
- A 36-year-old male developed jaundice and Lyell syndrome after therapeutic Tenoxicam (NSAID) use.
- Liver biopsy revealed cholestasis, non-suppurative cholangitis, and portal tract inflammation with eosinophils.
- Clinical recovery occurred within a year with ursodesoxycholic acid and cholestyramine, but mild cholestasis and ductopenia persisted for three years.
Findings:
- Tenoxicam toxicity was likely immunoallergic, evidenced by Lyell syndrome and histological eosinophils.
- Ductopenia appeared secondary to inflammatory cholangitis, with chronic evolution factors remaining unknown.
- Persistent ductopenia despite clinical recovery suggests compensatory bile drainage via cholangioles or biliary tree reconstruction.
Implications:
- This case underscores the potential for NSAIDs like Tenoxicam to induce severe, prolonged cholestatic injury.
- Immunoallergic mechanisms and secondary ductopenia are critical considerations in drug-induced liver injury.
- The findings suggest the liver's capacity for compensatory biliary adaptation in the face of chronic damage.